Table 3.
The top 20 pathways (Emp-p < 0.05) by using PASCAL tool
| Pathway | Chi2 P value |
Emp P value |
|---|---|---|
| FEV1 | ||
| REACTOME signalling by NGF | 3.22E-04 | 7.10E-05 |
| REACTOME NGF signalling via TRKA from the plasma membrane | 8.05E-04 | 1.44E-04 |
| KEGG p53 signaling pathway | 8.15E-04 | 1.61E-04 |
| BIOCARTA IL7 pathway | 7.04E-04 | 5.10E-04 |
| BIOCARTA IL4 pathway | 7.04E-04 | 7.40E-04 |
| REACTOME olfactory signaling pathway | 1.15E-03 | 7.60E-04 |
| BIOCARTA IL2 pathway | 7.04E-04 | 7.60E-04 |
| BIOCARTA IL2RB pathway | 7.04E-04 | 8.30E-04 |
| REACTOME digestion of dietary carbohydrate | 8.72E-04 | 1.02E-03 |
| REACTOME activated AMPK stimulates fatty acid oxidation in muscle | 1.68E-03 | 1.12E-03 |
| REACTOME passive transport by aquaporins | 1.33E-03 | 1.28E-03 |
| BIOCARTA ARAP pathway | 1.26E-03 | 1.30E-03 |
| REACTOME amine derived hormones | 1.41E-03 | 1.37E-03 |
| KEGG insulin signaling pathway | 1.86E-03 | 1.53E-03 |
| REACTOME APC C CDC20 mediated degradation of mitotic proteins | 1.61E-03 | 1.58E-03 |
| KEGG spliceosome | 1.44E-03 | 1.65E-03 |
| KEGG olfactory transduction | 2.56E-03 | 1.72E-03 |
| REACTOME autodegradation of CDH1 by CDH1 APC C | 1.61E-03 | 1.86E-03 |
| KEGG small cell lung cancer | 3.32E-03 | 1.88E-03 |
| REACTOME collagen formation | 5.69E-03 | 2.11E-03 |
| FVC | ||
| REACTOME insulin receptor signalling cascade | 2.37E-04 | 1.53E-04 |
| REACTOME FRS2 mediated cascade | 2.37E-04 | 1.68E-04 |
| REACTOME signaling by insulin receptor | 2.37E-04 | 1.85E-04 |
| REACTOME signalling by NGF | 1.35E-03 | 2.77E-04 |
| REACTOME NGF signalling via TRKA from the plasma membrane | 1.48E-03 | 3.11E-04 |
| REACTOME tandem pore domain potassium channels | 8.98E-04 | 3.24E-04 |
| REACTOME collagen formation | 1.14E-03 | 3.38E-04 |
| REACTOME SHC mediated cascade | 1.03E-03 | 4.47E-04 |
| REACTOME signaling by FGFR mutants | 1.03E-03 | 4.56E-04 |
| REACTOME FGFR ligand binding and activation | 1.03E-03 | 4.57E-04 |
| REACTOME FGFR2C ligand binding and activation | 1.03E-03 | 4.68E-04 |
| REACTOME negative regulation of FGFR signaling | 1.03E-03 | 4.71E-04 |
| REACTOME PI3k cascade | 1.03E-03 | 5.30E-04 |
| REACTOME activated point mutants of FGFR2 | 1.03E-03 | 5.60E-04 |
| REACTOME downstream signaling events of b cell receptor BCR | 1.42E-03 | 6.10E-04 |
| REACTOME phospholipase C mediated cascade | 1.03E-03 | 6.30E-04 |
| REACTOME signaling by the B cell receptor BCR | 1.40E-03 | 6.40E-04 |
| BIOCARTA IL7 pathway | 7.04E-04 | 6.50E-04 |
| BIOCARTA IL 4 pathway | 7.04E-04 | 7.20E-04 |
| BIOCARTA IL 2 pathway | 7.04E-04 | 7.40E-04 |
| FEV1/FVC | ||
| REACTOME influenza viral RNA transcription and replication | 5.97E-04 | 1.77E-04 |
| REACTOME apoptosis | 8.12E-04 | 1.83E-04 |
| KEGG ubiquitin mediated proteolysis | 5.44E-04 | 1.96E-04 |
| REACTOME p75 NTR receptor mediated signalling | 1.42E-03 | 3.82E-04 |
| KEGG WNT signaling pathway | 1.16E-03 | 5.46E-04 |
| BIOCARTA keratinocyte pathway | 3.40E-03 | 6.90E-04 |
| BIOCARTA TNFR1 pathway | 4.70E-03 | 1.14E-03 |
| BIOCARTA stress pathway | 5.94E-03 | 1.30E-03 |
| REACTOME peptide chain elongation | 2.30E-03 | 1.35E-03 |
| KEGG glycosphingolipid biosynthesis ganglio series | 1.39E-03 | 1.38E-03 |
| REACTOME SRP dependent cotranslational protein targeting to membrane | 2.30E-03 | 1.39E-03 |
| KEGG ribosome | 2.30E-03 | 1.46E-03 |
| REACTOME transferrin endocytosis and recycling | 2.47E-03 | 1.49E-03 |
| BIOCARTA TID pathway | 6.30E-03 | 1.58E-03 |
| BIOCARTA RELA pathway | 1.80E-03 | 1.71E-03 |
| REACTOME insulin receptor recycling | 2.47E-03 | 1.78E-03 |
| BIOCARTA p35 alzheimers pathway | 1.59E-03 | 1.78E-03 |
| BIOCARTA sodd pathway | 1.80E-03 | 1.78E-03 |
| BIOCARTA ceramide pathway | 1.80E-03 | 1.82E-03 |
| BIOCARTA NFKB pathway | 1.80E-03 | 1.88E-03 |